DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

Phase 1

Completed

Conditions: Solid Tumors
Breast Cancer
Cowden Syndrome

Interventions: Drug: BGT226

First Posted Date: 2008-01-24

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 57

Registration Number: NCT00600275

Locations: 🇺🇸
Nevada Cancer Center, Las Vegas, Nevada, United States
🇨🇦
Princess Margaret Hospital, Toronto, Canada
🇪🇸
Novartis Investigative Site, Barcelona, Spain

and more 3 locations

Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease

Phase 2

Terminated

Conditions: Crohn's Disease

Interventions: Drug: Placebo
Drug: AIN457

First Posted Date: 2008-01-02

Last Posted Date: 2015-03-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 59

Registration Number: NCT00584740

Locations: 🇩🇪
Novartis Investigative Site, Stuttgart, Germany

Effect of AQW051 in Patients With Memory Impairment

Phase 2

Terminated

Conditions: Mild Alzheimer's Disease
Amnestic Mild Cognitive Impairment

Interventions: Drug: AQW051
Drug: Placebo

First Posted Date: 2007-12-28

Last Posted Date: 2016-04-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT00582855

Locations: 🇬🇧
Novartis Investigator Site, Swindon, United Kingdom

Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection

Phase 2

Terminated

Conditions: Recurrent Hepatitis C

Interventions: Drug: CsA-TAC (standard Treatment)
Drug: Everolimus

First Posted Date: 2007-12-28

Last Posted Date: 2012-09-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 43

Registration Number: NCT00582738

Locations: 🇦🇷
Novartis Investigative site, Buenos Aires, Argentina

QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis

Phase 2

Terminated

Conditions: Pulmonary Fibrosis Secondary to Systemic Sclerosis

Interventions: Drug: QAX576
Drug: Placebo

First Posted Date: 2007-12-28

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT00581997

Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea

Phase 3

Completed

Conditions: Chemotherapy-induced Diarrhea

Interventions: Drug: Octreotide Long Acting Release
Other: Standard Treatment

First Posted Date: 2007-12-28

Last Posted Date: 2015-05-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 139

Registration Number: NCT00582426

Locations: 🇧🇷
Biocâncer, Belo Horizonte, Brazil
🇧🇷
Hospital Sao Lucas- Faculdade de Medicina da PUCRS, Porto Alegre, Brazil
🇧🇷
Clínica AMO, Salvador, Brazil

and more 8 locations

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients

Phase 4

Completed

Conditions: Heart Transplantation

Interventions: Drug: Enteric-coated Mycophenolate Sodium

First Posted Date: 2007-12-17

Last Posted Date: 2011-11-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 162

Registration Number: NCT00574743

Locations: 🇦🇷
Argentina, Buenos Aires, Argentina
🇨🇦
Novartis Investigative, Edmonton, Alberta, Canada
🇦🇷
Site 1: X5000BJH, Cordoba, Argentina

and more 6 locations

Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: AEB071

First Posted Date: 2007-12-13

Last Posted Date: 2020-12-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT00572585

Locations: 🇵🇱
Novartis Investigative Site, Poznan, Poland

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: placebo
Drug: indacaterol
Drug: indacaterol/glycopyrrolate

First Posted Date: 2007-12-11

Last Posted Date: 2018-07-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 154

Registration Number: NCT00570778

Locations: 🇳🇱
Novartis Investigator Site, Veldhoven, Netherlands
🇳🇱
Novartis Investigator site, Eindhoven, Netherlands
🇳🇱
Novartis investigator site, Heerlen, Netherlands

A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: LBH589

First Posted Date: 2007-12-10

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT00570284

Locations: 🇨🇭
Novartis Investigative Site, Zurich, Switzerland

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy